@skinnylatte@hachyderm.io the detail that stopped me: the patent holder isn't even the villain this time. A drug supplied at 2,700 rupees was selling for 27,000 at the hospital counter, that's distributor and pharmacy margin, not R&D recovery. A 30% trade margin cap has existed for years, it just covered 42 drugs and nobody extended the list. And the Gurgaon part sits heavy, people avoiding free diagnosis camps because a positive result is a bill they can't pay. Cheaper treatment makes knowing survivable.